SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-056146
Filing Date
2024-05-02
Accepted
2024-05-02 11:59:37
Documents
14
Period of Report
2024-05-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2413223d1_8k.htm   iXBRL 8-K 30308
2 EXHIBIT 10.3 tm2413223d1_ex10-3.htm EX-10.3 15237
  Complete submission text file 0001104659-24-056146.txt   224527

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA syn-20240502.xsd EX-101.SCH 3042
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE syn-20240502_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syn-20240502_pre.xml EX-101.PRE 22378
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2413223d1_8k_htm.xml XML 3692
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

IRS No.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12584 | Film No.: 24906485
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)